China's Type 2 Diabetes Market Will Grow To $3.5 Billion In 2017
Western-Branded Therapies Earn More Than 70 Percent of the Market in Sales,
According to a New Report from Decision Resources
BURLINGTON, Mass., Aug. 8, 2013
BURLINGTON, Mass., Aug. 8, 2013 /PRNewswire/ -- Decision Resources, one of the
world's leading research and advisory firms for pharmaceutical and healthcare
issues, forecasts that the type 2 diabetes therapeutic market in China, the
third largest after the United States and Japan, will grow 10 percent
annually, reaching $3.5 billion in 2017. Fueling this expansion are the
growing number of drug-treated patients and the increasing use of dipeptidyl
peptidase-4 (DPP-IV) inhibitors, glucagon-like peptide 1 (GLP-1) receptor
agonists and insulin analogues.
The Emerging Markets report entitled Type 2 Diabetes in China finds that,
although further generic erosion of older oral antidiabetics is expected,
recently launched DPP-IV inhibitors (Merck's Januvia/Janumet, Bristol-Myers
Squibb/AstraZeneca's Onglyza, Novartis's Galvus) and GLP-1 receptor agonists
(Bristol-Myers Squibb/AstraZeneca's Byetta, Novo Nordisk's Victoza) will
continue to enjoy market exclusivity and garner higher patient share in China
during the 2012-2017 period. Biosimilar versions of insulin analogues, both
long- and short-acting, will have only a modest impact on China's type 2
diabetes market during the forecast period. Most biosimilar insulins are only
fractionally less expensive than the originators, which encourages physicians
and patients to stay with branded insulins. Together with the launches of
additional novel agents, Western-branded therapies will consistently capture
more than 70 percent of sales in China's type 2 diabetes therapeutic market by
The findings also reveal that Chinese physicians show strong interest in
DPP-IV inhibitors and GLP-1 receptor agonists. DPP-IV inhibitors are favored
because of their improvement in glycemic control without the risk of
hypoglycemia. GLP-1 receptor agonists are effective in lowering HbA[1c] and
body weight and therefore are ideal for obese type 2 diabetes patients.
However, due to their high prices and lack of reimbursement, physicians who
currently prescribe them do so mostly in the second- or third-line setting,
after their patients fail to maintain glycemic control with less expensive
options. Meanwhile, patients need to be in good financial standing to afford
the high out-of-pocket payment.
"More than 95 percent of Chinese residents have access to some form of
government-sponsored medical insurance, but broad access does not translate
into affordable healthcare," said Decision Resources Analyst Jing Wu, M.S.,
M.B.A. "Select DPP-IV inhibitors and GLP-1 receptor agonists have a reasonable
chance of being included on the next version of the National Reimbursement
Drug List (NRDL), likely to be released in 2014. However, in order to control
treatment costs, the reimbursement of these agents will be restricted to
specific type 2 diabetes patient groups."
The new report features extensive primary research with Chinese physicians as
well as a market outlook through 2017.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market
research publications, advisory services and consulting designed to help
clients shape strategy, allocate resources and master their chosen markets.
Decision Resources is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources Group at
All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.
For more information, contact:
Decision Resources Group
SOURCE Decision Resources
Press spacebar to pause and continue. Press esc to stop.